RVMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Revolution Medicines Inc (RVMD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong analyst support, significant upcoming catalysts in oncology, and a promising late-stage pipeline. Despite short-term technical neutrality and no immediate trading signals, the long-term growth potential outweighs the risks.
The MACD histogram is positive at 0.299, indicating bullish momentum. RSI is neutral at 67.532, suggesting no overbought or oversold conditions. Moving averages are converging, showing no clear trend. Key resistance is at 99.65, with support at 92.407. The stock is trading near resistance, but the overall technical indicators are neutral.
Strong analyst ratings with multiple Buy and Overweight ratings from top firms. Price targets range from $115 to $150, significantly above the current price. Upcoming Phase 3 RASolute 302 readout in H1 2026 is a major catalyst with high confidence in positive results. The company is considered a potential M&A target due to its innovative oncology pipeline.
Recent news of a stock sale could lead to minor short-term dilution concerns. Financials show no revenue and significant net losses, which may deter risk-averse investors. Options data shows bearish sentiment with a high put-call ratio, indicating caution in the short term.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net loss of -$364.89M, though this was an 87.54% improvement YoY. EPS improved to -1.88, up 67.86% YoY. While financials show no profitability, the improvement in net income and EPS reflects better cost management.
Analysts have a highly positive outlook on RVMD, with multiple firms raising price targets significantly. Jefferies, UBS, and others highlight the company's innovative RAS inhibitors and potential in oncology. The consensus is that Revolution Medicines has one of the highest-quality late-stage pipelines in the industry.
